Breakthrough in joint injury treatments helps restore healthy activity and reduce pain
An Australian skin science technology company is set to revolutionise the treatment of joint injuries and osteoarthritis after a wearable patch product proved to be better at reducing pain than the world-leading non-steroidal anti-inflammatory drug (NSAID) product Voltaren.
OBJ Ltd’s BodyGuard technology will see a range of wearable products, adhesive patches and applicator devices supporting healthy ageing and more active lifestyles for the benefit of those suffering from joint related injuries and degeneration.
BodyGuard uses OBJ’s proprietary technology to drive Lubricen, a proprietary formulation comprised of key nutritional and structural ingredients, directly into the joint cavity. The effectiveness was recently confirmed in an FDA-compliant, double blind clinical trial across 114 males with a history of knee injury, conducted at the University of Queensland.
BodyGuard was found to reduce worst pain scores in patients suffering from mild to moderate knee osteoarthritis by 32 per cent, in stark contrast to Voltaren, which scored just 17 per cent.
By using a transdermal approach BodyGuard has been able to bypass first-pass metabolism that breaks down traditional orally ingested products. This allows the key joint restoration molecules to be delivered to the joint in their full ‘intact’ form, rather than in a partially digested form as is the case for ingested ingredients.
OBJ managing director Jeff Edwards said: “BodyGuard has the potential to provide a safe, more effective and easy to use method of restoring and maintaining a physically active lifestyle, even for those already suffering from joint pain and osteoarthritis. While the use of wearable technology for joint pain management may be new, the feedback from our recent trial highlights the appeal of this new approach to long-term joint health maintenance.”